ClinicalTrials.gg
Active, not recruitingNCT07932444Updated Nov 12, 2026

Melatonin in Stroke

An interventional study of Melatonin and Placebo in Stroke and CVA, sponsored by King Edward Medical University. Active, not recruiting at 1 site in Pakistan. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by King Edward Medical University · Not applicable, Interventional, and Treatment

Updated Nov 12, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 333 studies in Stroke with a site in Pakistan — 103 open to participants now, 134 under way, 1 of them phase 3. Stroke · Pakistan.

Planned enrollment
12th of 306
130 · median 42
Started
2026
with 52 others
No phase
300 of 333
99 open now
Primary completion
2027-09
later than 130 of 133 live
Registered
282nd of 333
by date

Among the 333 studies in Stroke with a site in Pakistan, this one is the 12th largest by planned enrollment of the 306 interventional ones that give a count, is one of 53 that started in 2026, is one of 300 with no phase, reaches primary completion later than 130 of the 133 other live ones, and was the 282nd registered.

Stroke

8,269 studies on the registry are indexed under Stroke; 2,062 are open to participants now.

Browse Stroke studies →

Open to participants now

103 of the 333 studies in Stroke with a site in Pakistan are open now. Recruiting first, the newest first:

98 more — sign in →

All 103 open studies →

A study can be open while its sites in Pakistan have not opened yet or have stopped. Only those recruiting at a site in Pakistan →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 696 (49%) set no upper age limit and 282 (20%) stop at 75 or younger; 77 take children under 18; 196 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 333 studies in Stroke with a site in Pakistan, or all of them as a file.
02

Study summary

Acute ischemic stroke (AIS) is a leading cause of mortality and disability worldwide, placing a substantial burden on healthcare systems and society.1 Despite intensive advancements in the stroke care, incomplete neurological recovery after stroke is quite common, with many survivors experiencing persistent motor, cognitive, or sensory deficits.2 These long-term impairments significantly affect the quality of life and highlight the need for additional neurorestorative therapies.3,4 The pathophysiology of ischemic stroke involves a complex cascade of events including excitotoxicity, oxidative stress, inflammation, and apoptosis, which contribute to neuronal injury and limit functional recovery.5,6 Current treatment strategies primarily focus on revascularization and supportive care, with limited options available to actively promote neuroprotection and regeneration.7,8 Melatonin, an endogenous neurohormone hormone primarily involved in regulating sleep-wake cycles, has been shown to possess several potential therapeutic properties, including antioxidant, anti-inflammatory, and neuroprotective effects.9 These properties have led to investigate the use of melatonin as an adjunctive treatment for various conditions, including stroke.10,11 However, its potential benefit in recovery of neurological status in patients with acute ischemic stroke remains understudied.12 Pre-clinical studies have demonstrated that melatonin can attenuate ischemia-induced brain injury, reduce infarct size, and improve functional outcomes.13 There is a compelling need to explore novel therapeutic interventions that can target neurological recovery in stroke patients. Exogenous melatonin administration offers a promising avenue for this intervention.14, 15 Preliminary studies have shown that melatonin may protect against acute ischemic stroke by suppressing both inflammatory and oxidative stresses.16 The purpose of this study is to evaluate the effects of exogenous melatonin supplementation on the neurological and functional recovery in patients with acute ischemic stroke, potentially leading to improved clinical outcomes. By addressing this research gap, the study seeks to provide valuable insights into the potential role of melatonin as a therapeutic agent in the management of acute ischemic stroke.

03

Conditions studied

  • Stroke
  • CVA

Browse trials for

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 40-70 years
  • Both male and female participants
  • Clinical diagnosis of acute ischemic stroke
  • National Institutes of Health Stroke Scale (NIHSS) score of 4-24
  • Not undergoing reperfusion therapy

Exclusion criteria

Exclusion Criteria:

  • Age less than 40 years or greater than 70 years
  • NIHSS score greater than or equal to 25
  • Hemorrhagic stroke or other intracranial pathologies
  • Chronic liver disease, chronic kidney disease, or severe systemic illnesses
  • History of alcohol or substance abuse
  • Known allergy to melatonin
  • Diagnosis of a sleep disorder
  • History of shift work within the past year
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    melatonin group

    Dietary Supplement: Melatonin

  • Placebo comparator
    control group

    Other: Placebo

Interventions

  • Dietary supplementMelatonin

    Melatonin 5 mg tablet administered orally once daily, approximately 1 hour before bedtime, for 3 months.

  • OtherPlacebo

    Matching placebo tablet administered orally once daily, approximately 1 hour before bedtime, for 3 months.

06

What researchers measure

Primary outcomes

  1. Neurological recovery assessed by NIHSS

    Neurological recovery assessed by National Institute of Health Stroke Scale (NIHSS) at baseline, end of one month and end of three months. NIHSS measures stroke severity on a scale from 0 to 42 with higher scores indicating greater severity of stroke. A decrease is NIHSS score on sequential assessment would indicate neurological recovery.

    Time frame: 3 months

  2. Functional Recovery assessed by MRS

    Functional recovery assessed by Modified Rankin Scale (MRS) at baseline, end of one month and end of three months.

    Time frame: 3 months

07

Study locations

1 site
  • Department of Neurology, King Edward Medical University
    Lahore, Punjab Province, Pakistan
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Sep 2027, 11 months after the start.

Of 3,117 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 11 months is below that.

Counting every sponsor, half of 3,261 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2026
First posted
Nov 12, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07932444
Lead sponsor
King Edward Medical University
Responsible party
Sponsor
First posted
Nov 12, 2026
Start date
Oct 1, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Melatonin

Start the discussion